Literature DB >> 9665902

Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing.

J E Verne1, R Aubrey, S B Love, I C Talbot, J M Northover.   

Abstract

OBJECTIVES: To compare the feasibility of mass screening by flexible sigmoidoscopy with screening by faecal occult blood testing (Haemoccult) and both tests combined.
DESIGN: Patients were randomised to screening by flexible sigmoidoscopy, faecal blood testing, or both tests. The flexible sigmoidoscopy examinations were performed by a general practitioner.
SETTING: General practice.
SUBJECTS: 3744 patients aged 50-75 years. MAIN OUTCOME MEASURES: Uptake, positive results, detection of neoplasia, complications, and recall for diagnostic colonoscopy.
RESULTS: Uptake was significantly higher in the flexible sigmoidoscopy group (46.6%) than in the faecal blood test group (31.6%; P<0.001) or than in the group having both tests (30.1%; P<0.001). Telephone reminders increased uptake of sigmoidoscopy to 61.8%. In total, 1116 sigmoidoscopy examinations were performed without major complication. Polyps were found in 19. 3% (95% confidence interval 17.0% to 21.6%) but only 6.8% (5.3% to 8. 3%) had adenomas and 2.4% (1.5% to 3.3%) "high risk" adenomas. Cancer was detected in four subjects. The faecal blood test yielded positive results in 0.8% (0.2% to 1.4%) but missed at least one cancer and 30 cases of adenoma which were found by sigmoidoscopy in the combined group. Use of histological criteria-shown elsewhere to correlate with future risk of colorectal cancer-to select "positive" patients could reduce recall for diagnostic colonoscopy from about 20% to less than 5%.
CONCLUSIONS: Some of the predicted obstacles to screening with flexible sigmoidoscopy are surmountable. Clear evidence relating to efficacy will be obtained only from a randomised controlled trial.

Entities:  

Mesh:

Year:  1998        PMID: 9665902      PMCID: PMC28612          DOI: 10.1136/bmj.317.7152.182

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  20 in total

Review 1.  Participation in fecal occult blood screening: a critical review.

Authors:  S J Blalock; B M DeVellis; R S Sandler
Journal:  Prev Med       Date:  1987-01       Impact factor: 4.018

2.  Haemoccult compliance rates and reasons for non-compliance.

Authors:  V Box; S Nichols; R C Lallemand; P Pearson; P A Vakil
Journal:  Public Health       Date:  1984-01       Impact factor: 2.427

3.  Screening for colorectal cancer.

Authors:  M H Robinson; D P Berry; K D Vellacott; V Moshakis; J D Hardcastle
Journal:  Lancet       Date:  1993-07-24       Impact factor: 79.321

4.  Magnitude of risk for cancer in patients with colorectal adenomas.

Authors:  B C Morson; H J Bussey
Journal:  Br J Surg       Date:  1985-09       Impact factor: 6.939

5.  Synchronous neoplasms in patients with diminutive colorectal adenomas.

Authors:  M R Tripp; T R Morgan; R E Sampliner; F J Kogan; R L Protell; D L Earnest
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

6.  Do characteristics of adenomas on flexible sigmoidoscopy predict advanced lesions on baseline colonoscopy?

Authors:  T M Zarchy; D Ershoff
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

7.  Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas.

Authors:  F A Macrae; D J St John
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

8.  Screening for colorectal cancer in a Hungarian county.

Authors:  L Ujszászy; G Prónay; G Nagy; J Kovács; J Libor; K Minik
Journal:  Endoscopy       Date:  1985-05       Impact factor: 10.093

9.  Epidemiology of polyps in the rectum and sigmoid colon. Design of a population screening study.

Authors:  G Hoff; M Vatn; E Gjone; S Larsen; J Sauar
Journal:  Scand J Gastroenterol       Date:  1985-04       Impact factor: 2.423

10.  The prevention of invasive cancer of the rectum.

Authors:  V A Gilbertsen; J M Nelms
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

View more
  23 in total

1.  A time for change and a time for vision.

Authors:  A F Wright
Journal:  Br J Gen Pract       Date:  1999-12       Impact factor: 5.386

2.  The early detection of colorectal cancer in primary care.

Authors:  R Jones; T Kennedy
Journal:  Br J Gen Pract       Date:  1999-12       Impact factor: 5.386

3.  Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

4.  [Staging of colorectal cancer. Official recommendations of the Canadian Study Group on Preventive Medicine].

Authors: 
Journal:  Can Fam Physician       Date:  2001-09       Impact factor: 3.275

5.  Colorectal cancer screening. Recommendation statement from the Canadian task force on preventive health care.

Authors: 
Journal:  Can Fam Physician       Date:  2001-09       Impact factor: 3.275

Review 6.  Protagonist: population based endoscopic screening for colorectal cancer.

Authors:  W S Atkin; J M A Northover
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 7.  Access to health care for ethnic minority populations.

Authors:  A Szczepura
Journal:  Postgrad Med J       Date:  2005-03       Impact factor: 2.401

8.  Acceptance of flexible sigmoidoscopy as a screening examination for colorectal cancer in an outpatient clinic.

Authors:  S Gölder; W Vogt; H Lichti; H C Rath; A Kullmann; J Schölmerich; F Kullmann
Journal:  Int J Colorectal Dis       Date:  2006-07-04       Impact factor: 2.571

9.  A prospective randomized single-blind comparison of three methods of bowel preparation for outpatient flexible sigmoidoscopy.

Authors:  A L Gidwani; R Makar; D Garrett; R Gilliland
Journal:  Surg Endosc       Date:  2006-12-06       Impact factor: 4.584

10.  Cancer screening trials: nuts and bolts.

Authors:  Philip C Prorok; Pamela M Marcus
Journal:  Semin Oncol       Date:  2010-06       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.